The correct definition of left ventricular ejection fraction (LVEF) normal response to exercise is still debated. The lack of unanimous agreement firstly depends on the different normality criteria ...adopted in literature. In order to make ligh, we carefully reviewed several papers on this matter, and performed exercise radionuclide angiography (RNA), by multiple gated blood pool, in 2 different populations. I group: 39 normal subjects, selected on the basis of normal clinical examinations, ECG, X-ray film, exercise test, at rest LVEF greater than 50%: 20 males, mean age 43 +/- 13%. II group: 22 patients, abnormal from the clinical point of view, but elsewhere included in control groups: 13 males, mean age 54 +/- 9%. 14 of them refer only atypical chest pain, in 5 the sole abnormal finding is an exercise-induced ST depression greater than 1 mm, in 2 a left bundle branch block at rest, 1 patient suffers from X syndrome. Symptom limited exercise RNA was carried out by adopting a semi supine (40 degrees) cycloergometer, with a 25 watt initial workload and 25 watt subsequent increases every 3 minutes; count acquisition lasted 2 minutes, from the end of the 1st to the end of the 3rd, during each stage of the test.
I group: constant LVEF increment during exercise in all subjects: mean LVEF at rest was 65 +/- 8%, at maximum workload 80 +/- 8%: mean increase was 15 +/- 7%.
Gallium-67-citrate imaging has been recently proposed, in addition to endocardial biopsy, to detect myocardial inflammation in idiopathic dilated cardiomyopathy (IDCM). In order to evaluate the ...clinical usefulness of this method, 33 patients (pts) suffering from IDCM, 24 pts with various other cardiac diseases (inflammatory etiology in 7), and 11 controls underwent Gallium-67 scintigraphy (anterior and 30 degrees left anterior oblique projections; acquisition at 48 and 72 hrs). In 31 pts repeated scintigraphic examinations (at least two) were obtained. Scans were interpreted by two independent observers. Positivity of scintigrams was based on three different criteria: 1) myocardial activity greater than that of the sternum; 2) presence of focal myocardial activity; 3) semiquantitative index (index = activity of sternum/myocardial activity). Significant differences, either in the percentage of positive scans or in the values of the semiquantitative index, were found between controls and all pts with cardiac diseases. However, no difference was observed when comparing pts with IDCM to pts with other cardiac diseases. Finally, among the pts with cardiac disorders other than IDCM, the qualitative and semiquantitative results of the 7 pts with inflammatory etiology of the disease were similar to those obtained in the remaining 17. Of those pts who underwent longitudinal study, about a third showed modified scintigraphic results later on. No significant difference in behaviour was observed between IDCM and other cardiac disorders. Therefore, we conclude that Gallium 67-citrate imaging does not appear to be a suitable method for the identification of pts. with IDCM. The usefulness of this technique should be tested in samples of pts should previously selected with other more specific methods.
Forty-two children with advanced neuroblastoma who either failed with first-line therapy or relapsed after achieving a complete remission, were considered for treatment with ...131Imetaiodobenzylguanidine (131I-MIBG). We subdivided 42 cases into 5 groups, in accordance with the stage of disease at diagnosis, response to first-line therapy and relapse. A total of 99 courses of 131I-MIBG were administered with doses ranging from 2.8 to 6.0 GBq. One child received six courses, 3 four courses, 18 three courses, 6 two courses and 15 one course of 131I-MIBG. The total delivered dose in single measurable lesions ranged from 286 to 1691 cGy with an uptake factor ranging from 3% to 10%. We obtained a major response in primary tumors, and a long-term response was observed in 5 cases, lasting more than 2 years without further chemotherapy.
![[131I]metaiodobenzylguanidi...](http://api.summon.serialssolutions.com/2.0.0/image/issn/XR4PS5YY4K/0368-3249/small "[131I]metaiodobenzylguanidine therapy in advanced neuroblastoma")
